Cysteamine (CysH)

Molecular group: 
Metabolic markers
Molecule/Cell: 
Cysteamine (CysH)
Plasmodium strain: 
Plasmodium chabaudi chabaudi AS
pRBC infection titer: 
10^5
Mouse genetic background (Con): 
A/J
Experimental treatment group (EG): 
+ cysteamine hydrochloride (therapeutic treatment)
Lethal infection (Con): 
♂ yes (100%); ♀ yes (35%)
Lethal infection (EG): 
♂ yes (33-65%); ♀ yes (65-0%)
Pathology (Con): 
N.I.
Pathology (EG): 
N.I.
Parasitemia (EG vs Con): 
Delayed onset and decreased
Additional phenotypes (EG vs Con): 
The antimalarial effect and the effect on survival deminished when the onset of treatment was delayed; delayed ↑ of serum IFN-g and CCL2 (MCP-1) levels, ↓ serum CCL5 (RANTES) levels on d7 p.i., and similar serum levels of TNF, CCL4 (MIP-1b) and IL-10
Refs: 
Min-Oo et al., 2010, Exp Parasitol